

Please type a plus sign (+) inside this box → ☐

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.


<b>TRANSMITTAL FORM</b> (To be used for all correspondence after initial filing)	<b>Application Number</b>	09/786,666
	<b>Filing Date</b>	March 7, 2001
	<b>First Named Inventor</b>	Hawkins et al.
	<b>Group Art Unit</b>	Not yet assigned
	<b>Examiner Name</b>	Not yet assigned
<b>Total Number of Pages in This Submission</b>	<b>Attorney Docket Number</b>	15280-351100

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment / Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input checked="" type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition Routing Slip (PTO/SB/69) and Accompanying Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard
<b>Remarks</b> The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm and Individual name Townsend and Townsend and Crew LLP Joseph R. Snyder	Reg No. 39,381
Signature	<i>Joseph R. Snyder</i>
Date	October 1, 2001

CERTIFICATE OF MAILING		
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on this date:		
		October 1, 2001
Typed or printed name	Debra Ann DeBello	
Signature	<i>Debra A DeBello</i>	Date: October 1, 2001

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
SF 1275369 v1



#5

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231

On October 1, 2001

TOWNSEND and TOWNSEND and CREW LLP

By: Debra Ann DeBello  
Debra Ann DeBello

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

HAWKINS et al.

Application No.: 09/786,666

Filed: March 7, 2001

For: PTERIDINE NUCLEOTIDE  
ANALOGS

Examiner: Not yet assigned

Art Unit: Not yet assigned

RESPONSE UNDER 37 C.F.R. §§ 1.821-  
1.825

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

This communication is being submitted in response to the Notification of Defective Response and Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, mailed August 1, 2001. Applicants respectfully request reconsideration and further examination of the above-referenced patent application in view of the remarks presented herein.

REMARKS

The sequence listing was alleged to be in non-compliance with 37 CFR 1.821-1.825 for failing to comply with its requirements, and for the content of the computer readable form failing to comply with the requirements of 37 CFR 1.822 and/or 1.832. Applicant respectfully traverses. The Raw Sequence Error Report reports use of

09786666-DE1501